Vyome Therapeutics Listed

Clinical-stage biopharmaceutical developing novel medicines specifically for skin diseases caused by resistant microbes, where standard antibiotics/topicals fail.

Dermatology patients with hard-to-treat, refractory skin conditions where existing topical treatments fail due to microbial resistance.

Vyome does not sell directly to end patients or pharmacies for its marketed dermatology products; the commercial relationship runs through a single exclusive marketing partner, Sun Pharma, which invoices and manages the relationship with downstream customers in India while Vyome earns product-sale, royalty, and agent-fee revenue from Sun Pharma.

Vyome's dermatological products reach the Indian market through a licensing and marketing agreement with the Sun Pharma group of companies, which distributes and sells the products on a wholesale basis (products ship via common carrier, with control passing to Sun Pharma at shipment).

Vyome reaches the oncology and cancer-research community by presenting clinical trial results directly at major scientific conferences, such as its Phase 2 VT-1953 data presented at the 2026 AACR Annual Meeting.

Vyome communicates preclinical/clinical data to the scientific and medical community by publishing in peer-reviewed journals, such as its VT-1908 uveitis preclinical results in the Journal of Ophthalmic Inflammation and Infection (Springer-Nature).

Progressing lead candidate VB 1953 (topical treatment for antibiotic-resistant acne) through FDA-track clinical development.

Patented Dual Action Rational Therapeutics (DARTs) technology underlying its pipeline of preclinical new chemical entities designed to overcome antimicrobial resistance.

Licensed marketing rights for its Molecular Replacement Therapeutics (MRT) antifungal platform to a large specialty pharmaceutical company.

Vyome recognizes revenue from selling its dermatological products to its pharmaceutical marketing partner once performance obligations are satisfied (control passes on shipment via common carrier).

Under its licensing and marketing contracts, Vyome earns royalty payments from its pharmaceutical marketing partner in exchange for granting the right to distribute its products.

Vyome earns service fee revenue as an agent fee, calculated as a percentage of the amount Sun Pharma invoices its own customers for products Sun Pharma sells.

Vyome's total revenue across these streams was $31,591 for Q1 2026, down from $198,581 in Q1 2025, reflecting a still-small legacy commercial base ahead of broader pipeline commercialization.

R&D costs are expensed as incurred and consist of internal costs (employee compensation and overhead) plus external costs paid to clinical research organizations and other third-party vendors for clinical trials, statistical analysis/report writing, and regulatory compliance.

Total operating expenses were approximately $1.1 million for the quarter ended March 31, 2026 -- about $666,000 in R&D expenses and $478,000 in selling, general & administrative expenses.

Vyome designs its clinical programs to be lean and cost-efficient -- tailored to a focused patient pool with endpoints that matter -- as a deliberate strategy to control development costs.